期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | JOURNAL OF DRUG TARGETING LetPub Score 6.4
51 ratings
Rate
Reputation 7.6 Influence 5.3 Speed 7.0 | ||||||||||||||||
期刊簡稱 | J DRUG TARGET | ||||||||||||||||
ISSN | 1061-186X | ||||||||||||||||
E-ISSN | 1029-2330 | ||||||||||||||||
h-index | 80 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://www.tandfonline.com/toc/idrt20/current | ||||||||||||||||
在線稿件提交 | https://mc.manuscriptcentral.com/gdrt | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Informa Healthcare | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||
創刊年 | 1993 | ||||||||||||||||
每年文章數 | 69每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 2.21% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1061-186X%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Average 2 Month(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: About 75% | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 2 下一頁 末頁 (頁 | |
[JOURNAL OF DRUG TARGETING] 的評論 | 撰寫評論 |
作者: Rita Brook 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-02-02 10:11:53 評論於 Do each original strip require internal reference, or only the target protein?(0) 讚! | Rita Brook |
作者: Ogden Bernard 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 21:37:41 評論於 It has been 11 days since I submitted my manuscript, but it still shows as "with journal administrator." Is this normal?(0) 讚! | Ogden Bernard |
作者: Ogden Bernard 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 20:15:25 評論於 I submitted a review article 11 days ago, and it still shows "with journal administrator." Is this normal?(0) 讚! | Ogden Bernard |
作者: 24毕业大吉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 13:21:22 評論於 What is the submission status process for this journal? It has been 11 days since the submission of the review article, and it still shows "with journal administrator." Is this normal?(0) 讚! | 24毕业大吉 |
作者: 24毕业大吉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 13:20:19 評論於 The overview submission has been pending for 11 days now, and it still shows "with journal administrator." Is this normal?(0) 讚! | 24毕业大吉 |
作者: Ogden Bernard 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-09 09:26:54 評論於 It has been 11 days since submission, and it still shows "with journal administrator." Is this normal?(0) 讚! | Ogden Bernard |
作者: 玄冰姣妍 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-04-09 16:52:34 評論於 Three parallel original stripes with markers are needed(0) 讚! | 玄冰姣妍 |
作者: 凤凰院雪柳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-01-08 17:10:33 評論於 Is the article on clinical trials accepted?(0) 讚! | 凤凰院雪柳 |
作者: 凤凰院雪柳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-01-08 14:16:25 評論於 Clinical research accepted?(0) 讚! | 凤凰院雪柳 |
作者: Abner Louise 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-11-01 10:48:14 評論於 This magazine gives too much power to its reviewers, and the editors do not perform basic screening of their opinions(0) 讚! | Abner Louise |
作者: Abner Louise 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-31 20:16:43 評論於 Research focus: sharing experience on drug targets. Submitted on July 20, 2022, received feedback on September 7, 2022, from two reviewers, both of whose comments were constructive. The editor suggested reject & resubmit based on the reviewers' feedback. After making revisions according to the reviews, we resubmitted to the same journal on September 27, 2022. Received feedback on November 1, 2022, from a single reviewer, who was extremely irresponsible and only suggested rejection due to lack of innovation. The reviewer believes that the lack of innovation is because there have been previous studies on a certain drug targeting, without mentioning the key pathological process discussed in our article. Furthermore, the reviewer questioned our drug usage method (solution or other methods) despite us clearly stating in the experimental methods section that our usage method is the same as in our previous experiments, which we have elaborated on in past articles. In conclusion, the reviewer's expertise is lacking, and we are considering writing an email to the editor to complain about this reviewer(0) 讚! | Abner Louise |
作者: 瓦咔咔 領域: 医学 審稿時間: 6.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-07-27 09:56:23 評論於 It's pretty good. It took about four months from submission to acceptance. There were quite a few reviewers, around five or six, and their comments were also very constructive.(0) 讚! | 瓦咔咔 |
作者: zhousd84 領域: 医学 審稿時間: 1.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-02-25 01:40:29 評論於 December submission, January feedback for revision, two reviewers, major revisions, there were quite a few comments, luckily the editor did a great job, and it was accepted.(10) 讚! | zhousd84 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 22:01:24 評論於 4-6 pictures(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 15:55:05 評論於 Additive effect refers to the effect of using two drugs together is equal to the effect of using double the dose of each drug individually. If the therapeutic effect obtained by using two drugs combined is greater than the sum of the efficiency of the two single drugs, it is called a synergistic effect. How to judge whether the interaction between two drugs is a synergistic effect or an additive effect? Due to the many factors that affect efficacy in animal experiments or clinical treatment, unless the results are significantly larger than the sum of the effectiveness of each drug, it can be clearly determined that a synergistic effect has been achieved, otherwise it is generally referred to as an enhancing effect(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 破戒阳平 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 23:56:21 評論於 How many figures/tables do most journals require?(0) 讚! | 破戒阳平 |
作者: 陶宜三岁啦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 21:13:28 評論於 What is synergy? What is additive effect? What is the difference between the two?(0) 讚! | 陶宜三岁啦 |
作者: 灵空奇希 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-12 23:10:30 評論於 Please submit for review(0) 讚! | 灵空奇希 |
作者: 坠星惜巧 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-08-19 21:50:28 評論於 Review speed: 2.0 Research focus: Oncology drug Experience sharing: Submitted for a month and still no news(0) 讚! | 坠星惜巧 |
作者: 坠星惜巧 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-08-04 16:51:28 評論於 Is "under review" in the process of being reviewed or in the hands of the editor?(0) 讚! | 坠星惜巧 |
作者: 灵空奇希 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-07-07 15:09:32 評論於 The editor's suggestion is to make the modifications as soon as possible, but we will take two months to do so(0) 讚! | 灵空奇希 |
作者: 先天梓萱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-05-05 21:15:16 評論於 How long did it take for you to make the revisions after the first review?(0) 讚! | 先天梓萱 |
作者: 灵空奇希 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-03-12 14:14:17 評論於 Review Speed: 6.0 | Submission Hit Rate: 50.0 Experience Sharing: Submitted a review on targeted drugs, first review completed in one month, with major revisions suggested by the editor. The comments from two reviewers were constructive, and two new figures and an improved table were added as requested. Accepted after the second review two months later. Despite some difficulties, grateful for the outcome. The submission difficulty is moderate, with a total time of approximately within half a year. Graduating students may consider this option(0) 讚! | 灵空奇希 |
作者: 弘光三岁啦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-03-01 15:55:12 評論於 Do you need to provide original data?(0) 讚! | 弘光三岁啦 |
作者: 一吃就胖小天琪 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-07-13 09:41:44 評論於 Do you need to provide the original data?(0) 讚! | 一吃就胖小天琪 |
首頁 上一頁 1 2 下一頁 末頁 (頁 |
Contact us